gsk201102256k4.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending February 2011
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--
 


 Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
 
 
I give below details of changes in the interests of the under-mentioned person, a Person Discharging Managerial Responsibility, in the Ordinary Shares (ORDs) of GlaxoSmithKline plc as a result of awards made on 24 February 2011 as follows:
 
 
Award under
Ordinary shares
Mrs V A Whyte
2009 Share Value Plan
10,050
 
2009 Performance Share Plan
11,800
 
The 2009 Performance Share Plan award was made using an Ordinary Share price of £11.78, the closing price of Ordinary shares on 24 February 2011.
 
The Company and the Person Discharging Managerial Responsibility were advised of these transactions on 25 February 2011.
 
This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
 
 
V A Whyte
Company Secretary
 
25 February 2011
 



SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: February 25 2011
 
 
By: VICTORIA WHYTE
------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc